XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.2.2
Collaboration and license agreements (Tables)
 9 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Summary of allocation of transaction price
The following table summarizes the allocation of the total transaction price to the identified performance obligations under the Roche Agreement, and the amount of the transaction price unsatisfied as of September 30, 2022 (in thousands):
Transaction
Price
Allocated		Transaction
Price
Unsatisfied
Performance obligations:  
Research and development targets$61,074 $25,933 
Option rights6,748 2,502 
Total$67,822 $28,435 
Schedule of revenue from collaboration agreements
Revenue from collaboration agreements for the three and nine months ended September 30, 2022 and 2021 in the condensed consolidated statements of operations and comprehensive loss was as follows (in thousands):
 Three Months Ended September 30,Nine Months Ended September 30,
 2022202120222021
Revenue from collaboration agreements:  
Roche Agreement$875 $2,330 $4,548 $7,416 
Biogen Agreement4,100 4,827 18,350 9,647 
Calico Agreement1,779 1,343 5,344 8,644 
Total revenue from collaboration agreements$6,754 $8,500 $28,242 $25,707 
Schedule of financial information related to collaboration and license agreements
Financial information related to the collaboration and license agreements consisted of the following in the Company’s condensed consolidated balance sheet as of September 30, 2022 (in thousands):
 Accounts
Receivable		Deferred Revenue,
Current		Deferred Revenue,
Net of Current		Deferred Revenue,
Total
Supplemental information:    
Roche Agreement$250 $4,754 $16,765 $21,519 
Biogen Agreement— 12,292 — 12,292 
Calico Agreement1,238 1,083 — 1,083 
Total$1,488 $18,129 $16,765 $34,894 
Financial information related to the collaboration and license agreements consisted of the following in the Company’s condensed consolidated balance sheet as of December 31, 2021 (in thousands):
 Accounts
Receivable		Deferred Revenue,
Current		Deferred Revenue,
Net of Current		Deferred Revenue,
Total
Supplemental information:    
Roche Agreement$1,215 $5,601 $17,215 $22,816 
Biogen Agreement3,000 24,032 6,611 30,643 
Calico Agreement1,501 2,167 542 2,709 
Total$5,716 $31,800 $24,368 $56,168 
Schedule of supplemental financial information related to collaboration and license agreements
Supplemental financial information related to the collaboration and license agreements for the three and nine months ended September 30, 2022 and 2021 are (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Revenue recognized that was included in the contract liability at the beginning of the period$5,517 $7,479 $24,005 $17,060 
Revenue recognized from performance obligations fully or partially satisfied in previous periods$— $— $518 $713